PERFORM: A Phase II Study of Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
University of Utah
Summary
The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Subjects aged ≥ 18 years. * ECOG Performance Status ≤ 2. * Histologically confirmed MCL or MZL, including EMZL/MALT lymphoma, SMZL, and NMZL. --Patients with gastric MALT lymphoma and those who are H. Pylori positive need to have failed a trial of H. Pylori eradication and are either ineligible, have refused, or have failed gastric radiation therapy. * Have received at least two prior lines of systemic therapy and do not have FDA approved available therapies or have refused them. * Prior autologous hematopoietic cell transplantation (auto-HCT) and CAR-T cell therapy a…
Interventions
- DrugPemigatinib
Pemigatinib will be self-administered as a once-a-day oral treatment on a 28-day cycle.
Location
- Huntsman Cancer Institute at University of UtahSalt Lake City, Utah